Shire to Present Scientific Data at American Psychiatric Association Annual Meeting

 Shire to Present Scientific Data at American Psychiatric Association Annual                                    Meeting  PR Newswire  PHILADELPHIA, May 2, 2014  PHILADELPHIA, May 2, 2014 /PRNewswire/ --  Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces that seven posters highlighting scientific data and clinical research will be presented at the upcoming American Psychiatric Association (APA) 167^th Annual Meeting in New York City, May 3 to May 7, 2014. These data represent Shire's ongoing commitment to clinical research and to understanding the unmet needs of patients.  "Improving the diagnosis and care of people living with mental health disorders is a priority for Shire" said Phil Vickers, Global Head of Research and Development for Shire. "For example, the research Shire is presenting at APA exemplifies our commitment to better understanding binge eating disorder and the needs of the adult patients who suffer from it."  Scientific Poster Presentations:  The titles and dates of the APA scientific presentations are noted below. Specific information about the data contained in these scientific presentations is embargoed until the start of the meeting.    o(Poster Number NR3-107; Sunday May 4, 10:30am EDT): Characteristics of     Patients with BED Compared to Patients with EDNOS and Patients Without an     Eating Disorder; Presented by Brandon Bellows, Pharm. D   o(Poster Number NR6-990; Monday May 5, 2:30pm EDT): Lisdexamfetamine     Dimesylate Effects on Cytochrome P450 Substrate Pharmacokinetics in     Healthy Adults in an Open-Label, Randomized, Crossover Study; Presented by     James Ermer, MS   o(Poster Number NR6-97; Monday May 5, 2:30pm EDT): Prevalence and Frequency     of Residual Symptoms of Depression in US Adults; Presented byBryanDirks,     MD   o(Poster Number NR8-44; Tuesday May 6, 2:30pm EDT): Estimating the     Prevalence of Binge Eating Disorder in a Community Sample, Comparing     DSM-IV-TR and DSM-5 Criteria; Presented by Nicole Cossrow, Ph.D, MPH   o(Poster Number NR8-55; Tuesday May 6, 2:30pm EDT): Survey of Binge Eating     Disorder Recognition, Diagnosis, Treatment and Referral in US Physician     Practices; Presented by Dylan Supina, Ph.D   o(Poster Number NR8-53; Tuesday May 6, 2:30pm EDT): Binge Eating Disorder     Patient Characteristics and Barriers to Treatment: A Qualitative Study;     Presented by Barry K. Herman MD, MMM   o(Poster Number NR8-54; Tuesday May 6, 2:30pm EDT): Randomized Controlled     Safety and Efficacy Trials of Lisdexamfetamine Dimesylate for Adults With     Moderate to Severe Binge Eating Disorder; Presented by Susan McElroy, MD  About VYVANSE (lisdexamfetamine dimesylate)  Vyvanse is a prescription medicine currently only approved in the United States, Canada, Australia, several European countries (trade name: Elvanse^®/Tyvense^®) and Brazil (trade name: Venvanse™) for ADHD. Vyvanse should only be used to treat ADHD.  INDICATION  Vyvanse is a prescription medicine for the treatment of ADHD in patients 6 years and above.  IMPORTANT SAFETY INFORMATION  Vyvanse is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep in a safe place to prevent misuse and abuse. Selling or sharing Vyvanse may harm others and is illegal.    oDo not take Vyvanse if you or your child:         ois taking or has taken within the past 14 days an anti-depression          medicine called a monoamine oxidase inhibitor or MAOI        ois sensitive to, allergic to, or had a reaction to other stimulant          medicines    oSome people have had the following problems when taking stimulant     medicines, such as Vyvanse:  1. Heart-related problems including:     osudden death in people who have heart problems or heart defects   osudden death, stroke and heart attack in adults   oincreased blood pressure and heart rate  Tell your doctor if you or your child has any heart problems, heart defects, high blood pressure, or a family history of these problems. The doctor should check your or your child's blood pressure and heart rate regularly during treatment.  Call your doctor right away if you or your child has any signs of heart problems such as chest pain, shortness of breath, or fainting while taking Vyvanse.  2. Mental (psychiatric) problems including:    onew or worse behavior and thought problems   onew or worse bipolar illness  In Children and Teenagers    onew psychotic symptoms such as:          oseeing things or hearing voices that are not real           obelieving things that are not true        obeing suspicious    onew manic symptoms  Tell your doctor about any drug abuse, alcohol abuse or mental problems that you or your child has had, or about a family history of suicide, bipolar illness, or depression.  Call your doctor right away if you or your child has any new or worsening mental symptoms or problems while taking Vyvanse.  3. Circulation problems in fingers and toes [Peripheral vasculopathy,including Raynaud's phenomenon]:    oFingers or toes may feel numb, cool, painful, sensitive to temperature     and/or change color from pale, to blue, to red  Call your doctor right away if you have or your child has any of these signs or symptoms or develops unexplained wounds on fingers or toes while taking Vyvanse.    oTell the doctor if you or your child is pregnant, breast-feeding, or plans     to become pregnant or breast-feed.   oVyvanse may cause serious side effects, including:         oslowing of growth (height and weight) in children. Your child should          have his or her height and weight checked often while taking Vyvanse.          The doctor may stop treatment if a problem is found during these          check-ups.    oThe most common side effects reported in studies of Vyvanse were:         oanxiety        odecreased appetite        odiarrhea        odizziness        odry mouth        oirritability        oloss of appetite        onausea        otrouble sleeping        oupper stomach pain        ovomiting        oweight loss  For additional safety information, click here forPrescribing InformationandMedication Guideand discuss with your doctor.  NOTES TO EDITORS  Shire enables people with life-altering conditions to lead better lives.  Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.  We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine, and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.  http://www.shire.com  FORWARD-LOOKING STATEMENTS - "SAFEHARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995  Statements included in this announcement that are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:    oShire's products may not be a commercial success;   orevenues from ADDERALL XR are subject to generic erosion and revenues from     INTUNIV will become subject to generic competition starting in December     2014;   othe failure to obtain and maintain reimbursement, or an adequate level of     reimbursement, by third-party payors in a timely manner for Shire's     products may impact future revenues, financial condition and results of     operations;   oShire conducts its own manufacturing operations for certain of its Rare     Diseases products and is reliant on third party contractors to manufacture     other products and to provide goods and services. Some of Shire's products     or ingredients are only available from a single approved source for     manufacture. Any disruption to the supply chain for any of Shire's     products may result in Shire being unable to continue marketing or     developing a product or may result in Shire being unable to do so on a     commercially viable basis for some period of time.   othe development, approval and manufacturing of Shire's products is subject     to extensive oversight by various regulatory agencies and regulatory     approvals or interventions associated with changes to manufacturing sites,     ingredients or manufacturing processes could lead to significant delays,     increase in operating costs, lost product sales, an interruption of     research activities or the delay of new product launches;   othe actions of certain customers could affect Shire's ability to sell or     market products profitably. Fluctuations in buying or distribution     patterns by such customers can adversely impact Shire's revenues,     financial conditions or results of operations;   oinvestigations or enforcement action by regulatory authorities or law     enforcement agencies relating to Shire's activities in the highly     regulated markets in which it operates may result in the distraction of     senior management, significant legal costs and the payment of substantial     compensation or fines;   oadverse outcomes in legal matters and other disputes, including Shire's     ability to enforce and defend patents and other intellectual property     rights required for its business, could have a material adverse effect on     Shire's revenues, financial condition or results of operations;   oShire faces intense competition for highly qualified personnel from other     companies, academic institutions, government entities and other     organizations. Shire is undergoing a corporate reorganization and the     consequent uncertainty could adversely impact Shire's ability to attract     and/or retain the highly skilled personnel needed for Shire to meet its     strategic objectives;   ofailure to achieve Shire's strategic objectives with respect to the     acquisition of ViroPharma Incorporated may adversely affect Shire's     financial condition and results of operations;  and other risks and uncertainties detailed from time to time in Shire's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K.  Vyvanse^® is a registered trademark of Shire LLC.  For further information please contact: InvestorRelations JeffPoulton jpoulton@shire.com +1-781-482-0945  SarahElton-Farr seltonfarr@shire.com +44-1256-894157  Media GwenFisher gfisher@shire.com +1-484-595-9836  AudreyAbernathy aabernathy@shire.com +1-484-343-4616  SOURCE Shire plc  
Press spacebar to pause and continue. Press esc to stop.